Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.38 |
| ▸ | FEN1 | P39748 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.35 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768999 | 0.97 | CYP3A4 (0.45) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL24778682 | 0.95 | CYP3A4 (0.47) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL26167206 | 0.93 | CYP3A4 (0.38) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL16769049 | 0.91 | CYP3A4 (0.36) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL26672922 | 0.89 | CYP3A4 (0.36) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL16768998 | 0.88 | CYP3A4 (0.39) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL802765 | 0.87 | ESR2 (0.46) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL17527752 | 0.87 | CYP3A4 (0.37) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL12658807 | 0.86 | ESR2 (0.45) | CYP3A4CYP2C9APPS1PR1S1PR5 | |
| SCHEMBL15445840 | 0.86 | ESR2 (0.45) | CYP3A4CYP2C9APPS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | CTNND1, YWHAZ, DVL1 | CYP3A4 2750/4885CYP2C9 1546/4885APP 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.